# A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients

> **NCT02617615** · PHASE1 · UNKNOWN · sponsor: **Microbio Co Ltd** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** MB-110
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02617615
- **Lead sponsor:** Microbio Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-01
- **Primary completion:** 2018-06
- **Final completion:** 2018-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2017-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02617615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02617615, "A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02617615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*